ClinicalTrials.gg
RecruitingNCT07513818IMPULSIONUpdated Jun 5, 2026

Implementing Low-dose ct Lung Cancer Screening in France.

An interventional study of Low-dose computed tomography of the chest in Lung Cancer, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged 50 Years to 74 Years. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20,000
Allocation
Non-randomized
Ages
50 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 9 under way, none of them phase 3. Lung Neoplasms · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
Largest of 12
20,000 · median 235
Started
2026
with 1 other
No phase
8 of 19
5 open now
Registered
18th of 19
by date

Among the 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 8 with no phase, and was the 18th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

9 of the 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 50 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Lung Neoplasms by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

The main objective is to estimate the detection rate of lung cancer in the population screened by low-dose chest CT scans.

Read the detailed description

Low-dose CT screening (LDCT) allows for the detection of lung cancer at an early stage, enabling curative treatment. Large randomized controlled trials have demonstrated that LDCT reduces mortality in smokers.

The objective of the current research is not to confirm a reduction in mortality, but to show that screening can be safely implemented at a population level. Different modes of recruitment and invitation will be tested to ensure that LDCT can be implemented equitably. The role of artificial intelligence as an alternative to double human reading will also be assessed.

Screening strategy includes baseline, followed by 1-year LDCT, and a third LDCT 2 years later. Current smokers will be offered smoking cessation support.

The management of screen-detected lung nodules will follow the 2025 guidelines from the European Society of Thoracic imaging.

03

Conditions studied

  • Lung Cancer

Keywords

  • Screening
  • Lung cancer
  • Computed Tomography
  • X-Ray
  • Smoking cessation
04

Who can participate

Ages eligible
50 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 50-74 years
  • Active or former smoker having quit less than 15 years ago
  • Smoking history of at least 20 pack-years, or 15 cigarettes/day for 25 years or 10 cigarettes/day for 30 years
  • Affiliation with a social security scheme
  • Written prior to study participation

Temporary exclusion Criteria

  • Chest CT scan performed within the previous 12 months
  • Signs of respiratory infection (fever, productive cough)

Exclusion criteria

Exclusion Criteria:

  • Severe co-morbidities contraindicating exploration and/or management (including stereotactic surgery or radiotherapy) of lung cancers
  • Poor general status (PS2 and above)
  • Rest dyspnea (mMRC4)
  • Cancer under active surveillance by thoracic computed tomography (CT pr PET-CT)
  • Personal history of lung cancer
  • Symptoms raising suspicion of lung cancer (hemoptysis, unexplained weight loss, recent onset or modification of respiratory symptoms,…)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
20,000 participants (estimated)

Interventions

  • ProcedureLow-dose computed tomography of the chest

    Baseline low-dose CT acquisition, then at 1 year and 3 years to depict suspicious lung nodules

06

What researchers measure

Primary outcomes

  1. Lung cancer detection rate in the population screened using low-dose chest CT

    Number of individuals with detected cancer divided by the number of individuals included in the study, i.e., an intention-to-screen analysis.

    Time frame: 42 months

Secondary outcomes

  1. Evaluation of screening performance

    * True positives: positive screening result and confirmation of malignancy. * True negatives: negative screening result (absence of nodules, or nodules not meeting the criteria for a positive or indeterminate screening, see algorithms), including during retrospective review in cases where cancer is diagnosed within the following year. * False positives: positive screening result but malignancy not confirmed after appropriate investigation(s). * False negatives: CT screening considered negative, but cancer is diagnosed within the coming year and the CT scan is retrospectively interpreted as positive or indeterminate.

    Time frame: 42 months

  2. Exploration and comparison of several methods for identifying and inviting the target population

    The identification and invitation of participants will be carried out using a multimodal approach: local and national press campaigns, outreach to insured individuals aged 50 to 74 in certain regions, and through an ambassador network (healthcare professionals, institutional representatives, associations, and citizens aware of lung cancer screening). Screening support tools will be deployed, including: * A website with a calculator to help determine eligibility; * A telephone call center to assess eligibility. Inclusions : Inclusions will be carried out by the participant's primary care physician if they are an investigator, or by other volunteer general practitioners, in health centers; by secondary care providers; or via outreach programs. The inclusion visits or teleconsultations will allow verifying the eligibility criteria and obtaining electronic consent.

    Time frame: 18 months

  3. Measurement of participation rate

    The participation rate is defined as the number of individuals having performed at least one CT scan, divided by the number of eligible individuals.

    Time frame: 18 months

  4. Measurement of response rates to follow-up invitations

    The investigators will measure the participation rate to follow-up invitations following an indeterminate CT scan result

    Time frame: 42 months

  5. Measurement of adherence to screening rounds

    The investigators will measure the participation rate to screening at 1 year and 3 year

    Time frame: 18 months , 30 months & 54 months

  6. Measurement of the complication rate of invasive investigations in positive cases (true positives and false positives)

    For participants with a positive screening result, the procedures, results, and complications of diagnostic actions (PET, endoscopy, CT-guided or ultrasound-guided biopsy, surgery) will be collected from the participants' medical records . The rate of early-stage lung cancers among the lung cancers diagnosed following a CT screening will also be measured (Evaluation criterion: number of lung cancers diagnosed at stage I or II divided by the total number of diagnosed lung cancers).

    Time frame: 42 months

  7. Measurement of the adherence rate to the offered smoking cessation support

    The investigators will record the proportion of active smokers who either decline the systematically offered smoking-cessation assistance or fail to attend the scheduled appointment, as well as the factors underlying this refusal. The investigators will also assess smoking cessation rates during follow-up and identify their predictors.

    Time frame: 48 months

  8. Measurement of the adherence rate to smoking cessation support

    The investigators will record the proportion of active smokers who declined smoking-cessation support or did not attend the scheduled appointments

    Time frame: 48 months

  9. Identification of reasons for refusal of smoking cessation support.

    Investigators will collect the reasons selected by participants for refusing smoking cessation support from a pre-established list (e.g., concern about weight gain, fear of failure).

    Time frame: 48 months

  10. Measurement of smoking cessation rate

    The investigators will assess smoking cessation rates during follow-up and identify their predictors.

    Time frame: 48 months

  11. Identification of the predictors of smoking cessation rates.

    The investigators will identify the predictor of smoking cessation rates (correlation with age, gender, level of education, occupation, etc…)

    Time frame: 48 months

  12. Evaluation of the feasibility and relevance of a double reading of CT scans, and role of artificial intelligence

    * Agreement in classifying cases as "screen-negative" versus "positive or indeterminate" between a single AI-assisted reading and a double AI-assisted reading (with a third adjudication in case of disagreement, serving as the reference), measured using the kappa coefficient. * Agreement in classifying cases as "screen-negative" versus "positive or indeterminate" between AI alone and the reference, measured using the kappa coefficient.

    Time frame: 12 months

  13. Measurement of the detection rate of coronary artery calcifications, pulmonary emphysema, osteoporosis, and incidental findings

    For each of these anomalies, the detection rate will be calculated as the number of participants with the anomaly divided by the number of participants who underwent at least one CT scan. The presence and severity of emphysema (Fleischner classification), the Shemesh score, attenuation at the T8 level, and the diameter of the ascending aorta if \>4 cm will be systematically recorded in the structured CT screening report. Interstitial lung abnormalities (ILA, including Langerhans cell histiocytosis), osteoporotic compression fractures, and all anomalies requiring clinical care will also be systematically documented.

    Time frame: 24 months

  14. Impact of the program on healthcare pathways

    The impacts on care pathways can be measured by evaluating the following time intervals, -Time between registration on the platform and completion of the inclusion visit, * Time between inclusion and completion of the initial CT scan, * Time until availability of radiology reports (single and double reading), * Time to first contact with a tobacco cessation specialist AND Using the date of the CT scan as the reference date: * Time to presentation of positive cases at the MDTB, * Time to a positive diagnosis (pathological report or MDTB report ) * Time to first treatment for positive cases requiring it, * Time to the first thoracic surgery consultation, * Time to surgery * Time to other consultations depending on incidental findings

    Time frame: 42 months

  15. Comparison of healthcare pathways

    Healthcare utilization will be compared between screening-adherent and non-adherent patients, using two different denominators: the target population and the invited population after linkage with the SNDS (French National Health Data System).

    Time frame: 42 months

  16. Creation of a CT scan dataset

    As part of the IMPULSION study, an imaging dataset for research and teaching purposes will be created, including all CT scans performed during the study (baseline, follow-up, and subsequent screening rounds), unless the participant explicitly objects.

    Time frame: 42 months

  17. Definition of a lung cancer risk score

    Using the variables collected in the IMPULSION study, a predictive lung cancer risk score will be developed for the eligible population, specifically tailored to the French population.

    Time frame: 42 months

  18. Cost effectiveness analysis

    The costs associated with screening (including surgical treatment of early-stage cancers and hospitalization for invasive procedures) will be compared with the costs that would have been incurred if the screen-detected lung cancers had all been diagnosed at an advanced stage.

    Time frame: 42 months

  19. Panel characteristics of participants

    The objective of this sub-study is to conduct a qualitative analysis of the characteristics of participants in lung cancer screening and the program.

    Time frame: 48 months

  20. Panel - participant perceptions

    Qualitative assessment of participant perceptions regarding lung cancer screening in a random sample of 2,000 participants enrolled in the main study.

    Time frame: 48 months

  21. Ultra low-dose

    The objective is to assess whether this dose level, using modern techniques, provides information equivalent to that obtained with the dose used in the main protocol. A second ultra-low-dose acquisition (CTDI 0.15 mGy for weight \< 80 kg, CTDI 0.20 mGy for weight ≥ 80 kg) immediatly after the IMPULSION CT scan. The ultra-low-dose CT scan will be read exclusively in a centralized manner by a certified radiologist assisted by AI software, using the same criteria as those applied to the low-dose reference acquisition, and blinded to the low-dose CT data. An assessment of concordance will be performed in 2,500 participants.

    Time frame: 1 day (baseline scanner)

  22. Biobank

    Collection of a maximum of 28 mL of whole blood (i.e., approximately 7 tubes of 5 mL with 4 mL collected per tube) for storage for research purposes. The collected samples are intended to create a biobank linked to clinical and radiological data. This biobank will make it possible to test various biomarkers for predicting individual cancer risk, the risk that a nodule is cancerous, or the risk of developing a disease evaluated in this cohort (including COPD, cardiovascular disease, osteoporosis, or interstitial lung disease).

    Time frame: Inclusion (day 1)

  23. Spirometry

    The purpose of this examination is to assess lung volumes at inclusion visit. In participating an optional, spirometry will be performed at inclusion. The following mesaures will be recorded : FEV1 and FVC. Interpretation will be based on GOLD recommendations and using the GLI system for reference values. The following definitions will be used: * Pre-COPD: FEV₁ \< 80% and FEV₁/FVC ≥ 0.7 * Obstructive ventilatory defect (OVD): FEV₁/FVC \< 0.7 on spirometry * GOLD stages 1 to 4 according to the FEV₁ value. Participant questionnaire will also includes questions about chronic COPD symptoms in order to assess the presence of a COPD.

    Time frame: Inclusion (day 1)

07

Study locations

1 of 2 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2031, 60 months after the start.

Of 871 non-industry interventional studies with no phase under Lung Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 60 months is above that.

Counting every sponsor, half of 922 studies reached it within 34 months; a quarter within 15 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Apr 7, 2026
StartActual
May 11, 2026
Primary completionEst.
May 2031
CompletionEst.
Nov 2031
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07513818
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
May 11, 2026
Primary completion
May 2031 (estimated)
Completion
Nov 2031 (estimated)
Last update
Jun 5, 2026

Study contacts

Marie-Pierre REVEL, PhD
Contact
marie-pierre.revel@aphp.fr
01 58 41 24 71 ext. +33
Alice CAMARA, MSc
Contact
alice.camara@aphp.fr
01 71 76 07 64 ext. +33
Marie-Pierre REVEL, PhD
principal investigator · Assistance Publique - Hôpitaux de Paris
Sébastien COURAUD, PhD
study chair · Hospices Civils de Lyon

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion